


CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:




Formula (I)

wherein,

R₁ is selected from the group consisting of COOH, or a salt thereof, C(O)NR₉R₁₀, C(O)OR₁₁ wherein R₉, R₁₀ and R₁₁ are independently selected from the group consisting of hydrogen and optionally substituted C₁-C₆ alkyl;

R₃ is selected from the group consisting of optionally substituted N-linked tetrazole, optionally substituted N-linked indole, optionally substituted N-linked isoindole, optionally substituted N-linked benzotriazole, and N-linked triazole substituted at one or both ring carbon atoms having the below structure:



wherein, R₂₀ and R₂₁ are selected from the group consisting of hydrogen, hydroxyl, cyano, halo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkylether, optionally substituted pyridyl and optionally substituted phenyl, with the proviso that when R₂₀ is hydrogen and R₄ is AcHN then R₂₁ is selected from the group consisting of hydrogen, hydroxyl, cyano, halo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkylether, substituted pyridyl and substituted

phenyl wherein substitution of pyridyl and phenyl is independently with a moiety selected from the group consisting of methyl, propyl, isopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, pentyl, isoamyl, 2-methylbutyl, 3-methylbutyl, hexyl, C₁-C₆ haloalkyl, C₁-C₆ alkylhydroxy, C₁-C₂ alkoxy, carboxy and salts thereof, C₄-C₆ alkoxy, Cl, Br, I, and -CH₂OCH₃;


and wherein at least one of R₂₀ and R₂₁ is not hydrogen;

R₄ is NHC(O)R₁₇ wherein R₁₇ is selected from the group consisting of optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ haloalkyl and optionally substituted C₃-C₆ cycloalkyl;

R₆, R₇ and R₈ are independently selected from the group consisting of OH, NH₂, C₁-C₆ alkyl, NR₁₈R₁₈', C₁-C₆ alkoxy, -OC(O)R₁₈, -NH(C=O)R₁₈, and S(O)_nR₁₈, wherein n = 0 – 2 and each R₁₈ and R₁₈' are independently hydrogen or optionally substituted C₁-C₆ alkyl;

and with the proviso that when R₄ is NHAc and R₃ is a triazole substituted only at the R₂₁ position then the triazole is not substituted with propyl, substituted propyl, substituted *tert*-butyl or diethoxyalkyl.

2. The compound of claim 1 wherein R₁ is COOH, or a salt thereof, or C(O)OR₁₁ wherein R₁₁ is selected from methyl, ethyl and propyl.
3. The compound of claim 1 or claim 2 wherein R₃ is selected from the group consisting of:




wherein, R₂₀ and R₂₁ are as defined in claim 1;

R₂₂ is selected from the group consisting of hydrogen, C₁-C₆ alkyl and optionally substituted phenyl; and


R₂₃ and R₂₄ are independently selected from the group consisting of hydrogen, hydroxyl, cyano, halo, C₁-C₆ alkyl and C₁-C₆ haloalkyl.


4. The compound of claim 3 wherein when R₂₂ is optionally substituted phenyl then the substitution may be with a moiety selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkylhydroxy, C₁-C₆ alkoxy, halo, -C(O)OMe and -CH₂OCH₃.

5. The compound of any one of the preceding claims wherein R_3 is selected from the group consisting of:



6. The compound of any one of the preceding claims wherein R₄ is selected from the group consisting of:






and

7. The compound of any one of the preceding claims wherein R_4 is selected from the group consisting of $-NHAc$, $-NHC(O)CH_2(CH_3)_2$, $-NHC(O)CF_3$ and $-NHC(O)CH_2CH_3$.

8. The compound of any one of the preceding claims wherein R_6 , R_7 and R_8 are independently selected from OH and OAc .


9. The compound of any one of the preceding claims wherein the compound of formula (I) is a compound of formula (II):




Formula (II)

wherein, R_1 , R_3 , R_4 , R_6 , R_7 and R_8 are as described in any one of the preceding claims.

10. The compound of any one of the preceding claims wherein the compound of formula (I) or formula (II) is a compound selected from the group consisting of:





and analogues thereof wherein the C-2 carboxy group is in the protonated form, sodium salt form or C₁-C₃ ester prodrug form and wherein the R₄ position is substituted with any –NHC(O)R group wherein R is C₁-C₄ alkyl or haloalkyl.

11. A pharmaceutical composition comprising an effective amount of a compound of any one of claim 1 to claim 10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient.

12. Use of a compound of any one of claim 1 to claim 10, or a pharmaceutically effective salt thereof, or the pharmaceutical composition of claim 11, in the manufacture of a medicament for treating a disease, disorder or condition caused by parainfluenza virus.

13. The use of claim 12 wherein the parainfluenza virus is selected from the group consisting of the hPIV-1, 2 and 3 virus.

14. The use of claim 12 or claim 13 wherein the patient is a domestic or livestock animal or a human.

15. Use of a compound of any one of claim 1 to claim 10, or a pharmaceutically effective salt thereof in the manufacture of a medicament for inhibiting the activity of a parainfluenza hemagglutinin and/or neuraminidase enzyme.